5-Amino-1MQ: NNMT Inhibition and the Missing Human Trials
An NNMT-inhibiting small molecule studied for fat loss in obese mice — no human trials have been published as of 2026.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that helps fat cells store energy and that's been linked to obesity and metabolic dysfunction. In diet-induced-obese mice, blocking NNMT with 5-Amino-1MQ cut body weight by roughly 7%. It is not a peptide — it's a small molecule, popular in the same longevity/fat-loss research circles as NAD+ and MOTS-c. As of 2026, all efficacy evidence is animal-only; no human trial has been published.
Quick facts
- Class
- NNMT inhibitor (small molecule, not a peptide)
- Solubility
- Oral capsule — no reconstitution required
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO). No human trials published as of 2026
- Category
- Metabolic
- Storage
- Room temperature, sealed, away from light and moisture. No refrigeration or reconstitution required.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Weight Loss | Cgrade | Neelakantan 2018 (Biochem Pharmacol): -7% body weight in a diet-induced-obesity mouse model. No human trials published. |
5-Amino-1MQ Mechanism of Action
Blocking NNMT to Change Fat-Cell Metabolism
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme highly expressed in fat tissue that methylates nicotinamide, consuming a methyl-donor pool the cell would otherwise use for other metabolic processes. NNMT activity has been linked to fat-cell energy storage and to obesity in human observational data, which is the rationale for studying its inhibition as a fat-loss strategy.
Not a Peptide
Unlike most compounds in this catalog, 5-Amino-1MQ is a small molecule, not a peptide — structurally unrelated to amino-acid chains. It's grouped in the same research-vendor and longevity-community conversation as NAD+ and MOTS-c because of shared interest in metabolic/mitochondrial health, not because of any structural similarity.
5-Amino-1MQ Dosage and Protocols
Research Protocol Range
Research-vendor products are commonly dosed at 50–150mg orally once daily. Since no human trial exists, this range reflects informal research-community convention extrapolated from animal dosing, not a validated human dose-finding study.
5-Amino-1MQ Side Effects and Safety
No Human Safety Data
Because no human trial has been published, there is no characterized human side-effect profile for 5-Amino-1MQ. Active malignancy is treated as a precautionary contraindication given NNMT's broader role in cellular methylation metabolism, which has documented links to some cancer biology in unrelated research contexts.
5-Amino-1MQ Research Evidence
Animal Data Only
The primary supporting study (Neelakantan et al., 2018, Bioorg Med Chem Lett) showed that blocking NNMT with 5-Amino-1MQ reduced body weight by roughly 7% and lowered white-fat mass in a diet-induced-obesity mouse model. As of 2026, no human trial of 5-Amino-1MQ has been published — the entire efficacy case rests on this and related animal extrapolation.
Regulatory and Legal Status
5-Amino-1MQ is not FDA-approved for any indication and is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of 5-Amino-1MQ in their jurisdiction prior to purchase or use, and should weigh the complete absence of human trial data accordingly.
5-Amino-1MQ Stacking and Combinations
5-Amino-1MQ + NAD+ + MOTS-c
5-Amino-1MQ is frequently sold and used alongside NAD+ and MOTS-c in longevity/metabolic-health research protocols — all three are positioned around cellular energy metabolism, though no formal trial data exists for any combination.
5-Amino-1MQ Pharmacokinetics
Not Established in Humans
No human pharmacokinetic study — absorption, half-life, clearance — has been published for 5-Amino-1MQ. All available PK-adjacent data comes from the mouse model in the foundational efficacy study.
Contraindications
- pregnancy
- active malignancy
Trials and reviews
- Neelakantan diet-induced obesityBioorg Med Chem Lett2018
-7% body weight in obese mice; zero published human trials
Frequently asked questions
What is a typical 5-Amino-1MQ dose?
Published research protocols report 50–150 mg, 1x daily. This is the range described in the literature, not a recommendation.
What is the half-life of 5-Amino-1MQ?
Not established in humans.
Is 5-Amino-1MQ backed by strong evidence?
5-Amino-1MQ carries a REGEN research grade of C. REGEN Research Tier C — a mouse study only, no published human trials as of 2026.
How is 5-Amino-1MQ administered?
Routes reported in the literature: oral.
Who should avoid 5-Amino-1MQ?
Contraindications noted in the literature include pregnancy, active malignancy.